The Body Mass Index (BMI) has long been the default screening tool for obesity and metabolic risk, used by clinicians, insurers, and public health agencies worldwide. But a wave of new research, updated clinical guidelines, and shifting industry standards is now questioning whether BMI alone remains fit for purpose. At the recent European Congress on Obesity (ECO) in Dublin, and in parallel publications inThe Lancet Diabetes & Endocrinology, experts presented data suggesting that BMI’s limitations—particularly its inability to distinguish muscle from fat, and its poor performance across different ethnic groups—are no longer acceptable in an era of personalized medicine.

The Core Controversy: BMI’s Blind Spots

BMI, calculated as weight in kilograms divided by height in meters squared, was developed in the 1830s by Belgian statistician Adolphe Quetelet—not as a medical diagnostic, but as a population-level measure. Today, it remains the entry point for obesity diagnosis (BMI ≥30 in most Western countries), drug eligibility (e.g., GLP-1 receptor agonists), and surgical candidacy. Yet a growing body of evidence shows that BMI misclassifies a significant portion of the population.

A 2024 study published inJAMA Network Openanalyzed data from over 3,000 U.S. adults using dual-energy X-ray absorptiometry (DEXA) scans. The researchers found that nearly 40% of participants with a “normal” BMI (18.5–24.9) had body fat percentages in the obese range, while more than 30% of those classified as “overweight” (25–29.9) had healthy body fat levels. The authors concluded that BMI alone misses “metabolically obese normal-weight” individuals—who face elevated risks of type 2 diabetes, hypertension, and cardiovascular disease—while also flagging “metabolically healthy” people with high muscle mass, such as athletes, as overweight or obese.

Industry Response: From BMI to Body Composition

The response from the medical and fitness industries has been swift. In March 2025, the American Medical Association (AMA) issued a policy update recommending that BMI be used “in conjunction with other valid measures of risk, such as body composition, waist circumference, and metabolic markers,” rather than as a standalone criterion. This follows the AMA’s 2023 decision to formally acknowledge BMI’s limitations, but the new language goes further, urging clinicians to document discrepancies between BMI and actual adiposity.

Meanwhile, the global weight-loss drug market—projected to reach $150 billion by 2030—is recalibrating its eligibility criteria. Novo Nordisk and Eli Lilly, the makers of semaglutide (Wegovy) and tirzepatide (Zepbound), respectively, have both begun funding studies that incorporate body fat percentage measurements. In a recent investor call, Lilly’s chief medical officer noted that “relying solely on BMI may exclude patients who would benefit from pharmacotherapy, particularly those with central obesity and normal BMI.” Some private insurers in the U.S. and Europe have already started requiring waist-to-height ratio or bioelectrical impedance analysis (BIA) for coverage decisions.

Trend Analysis: The Rise of Digital Body Composition Tools

The shift is also driving innovation in measurement technologies. Traditional DEXA and MRI remain the gold standard for body composition analysis, but they are expensive and not widely accessible. In response, a new generation of consumer and clinical devices is emerging.

A report from market research firm Grand View Research, published in April 2025, projects the global body composition analyzer market to grow at a compound annual growth rate of 8.2% from 2025 to 2030, driven by clinical adoption and home-use demand. The report notes that “the traditional BMI-centric paradigm is being replaced by a multi-metric approach, with body fat percentage and fat distribution emerging as primary indicators.”

Expert Opinion: A Nuanced Path Forward

Dr. Priya Sharma, an endocrinologist at the University of Toronto and a co-author of theLancetposition paper, cautions against discarding BMI entirely. “BMI is not useless—it’s just insufficient,” she said in an interview. “For population-level surveillance and for identifying trends over decades, BMI remains a cheap, reproducible, and universally available metric. The danger is using it as a diagnostic endpoint for an individual.”

She advocates for a “two-step” approach: first, use BMI as a broad filter; second, for anyone at the boundaries (BMI 22–32 or with metabolic risk factors), perform a more precise body composition assessment. “We need to move from ‘what is your BMI?’ to ‘what is your body fat percentage, where is it distributed, and what is your metabolic profile?’”

Dr. James O’Connell, a sports medicine physician and advisor to the International Olympic Committee, echoes this. In his practice, he sees elite athletes with BMIs over 30 who are in peak cardiovascular health. “If we had relied on BMI, these athletes would have been denied insurance coverage or pushed into unnecessary interventions. The industry is finally catching up to what sports science has known for decades: muscle is not fat.”

Regulatory and Policy Implications

Regulators are also taking note. The U.S. Food and Drug Administration (FDA) is currently reviewing a citizen petition that requests a revision of the drug labeling language for anti-obesity medications, which currently states that BMI ≥30 (or ≥27 with comorbidity) is required for use. The petition, supported by several obesity medicine societies, argues that a BMI-only threshold discriminates against patients with high muscle mass and certain ethnic backgrounds. A decision is expected in late 2025.

In the insurance sector, the International Classification of Diseases (ICD-11), adopted by the WHO in 2022, already includes codes for “obesity due to excess calories” and “obesity with body fat percentage specified,” but the practical implementation varies by country. The UK’s National Institute for Health and Care Excellence (NICE) is updating its obesity guidelines for 2026, with a draft recommending that waist circumference—not BMI—be used as the primary screening tool in primary care settings.

Challenges and Criticisms

Despite the momentum, critics warn that replacing BMI with body composition metrics is not without problems. First, there is no universally accepted cutoff for “normal” body fat percentage; values vary by age, sex, and ethnicity. Second, BIA and other consumer devices can be inaccurate in hydrated or dehydrated states, leading to misclassification. Third, the cost of DEXA or MRI remains prohibitive for low-resource settings, potentially widening health inequities.

Dr. Maria Lopez, a public health researcher at Johns Hopkins, argues that “the pendulum may be swinging too fast. We risk creating a two-tier system where wealthy patients get precise body composition scans, while poorer populations are still judged by BMI—or worse, ignored entirely.” She calls for standardized, low-cost algorithms that can estimate body fat from simple measurements, and for global guidelines that are flexible enough for different healthcare budgets.

Outlook: A Hybrid Model Emerges

Industry consensus appears to be moving toward a hybrid model: BMI for screening, body composition for diagnosis, and metabolic biomarkers (fasting glucose, triglycerides, blood pressure) for risk stratification. This aligns with the broader trend in medicine toward precision health, where treatment decisions are based on an individual’s unique physiology rather than a population average.

For the fitness and wellness industry, the implications are clear. Gyms and health clubs are increasingly offering body composition assessments as a standard part of membership, and wearable manufacturers are integrating muscle mass and visceral fat tracking into their apps. For pharmaceutical companies, the shift means larger addressable markets—and more complex clinical trial endpoints. For patients, it means that a “normal” BMI may no longer be a clean bill of health, nor a high BMI a definitive diagnosis.

As the debate continues, one thing is certain: the era of BMI as the sole arbiter of metabolic health is ending. The question now is not whether to replace it, but how quickly—and with what combination of tools—the global health system can adapt.